Medline ® Abstract for Reference 110
of 'Clinical manifestations and diagnosis of Fanconi anemia'
Estimation of the prevalence of Fanconi anemia among patients with de novo acute myelogenous leukemia who have poor recovery from chemotherapy.
Rochowski A, Rosenberg PS, Alonzo TA, Gerbing RB, Lange BJ, Alter BP
Leuk Res. 2012 Jan;36(1):29-31. Epub 2011 Oct 4.
We speculated that some individuals with de novo acute myelogenous leukemia (AML) may have undiagnosed Fanconi Anemia (FA). Data from patients enrolled on AML protocol CCG-2961, published FA cohort studies, SEER, and Bayes rule were used to estimate the probability of FA among all newly diagnosed AML cases, and among those who had no or delayed recovery of the absolute neutrophil count following initial chemotherapy. We determined that the probability of undiagnosed FA in patients in a treatment trial for newly diagnosed patients was around 0.18%, and around 0.83% in the subset who had poor marrow recovery. We suggest that FA or other inherited bone marrow failure syndromes be considered prior to treatment, or certainly among those with poor recovery.
Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC, USA.